Xeris Biopharma Holdings, Inc. (XERS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$7.71-9.08%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Achieve and sustain positive net income: EPS -0.18 vs >0 target.
Xeris raised 2026 revenue guidance to about $385 million. Sales grew 38% from 2025-Q1 to 2026-Q1. Net income turned positive at $2.2 million in 2026-Q1. The company is fixing losses and growing steadily.
Litigation and capital deals may hurt finances. Profit gains could stall. Growth might slow below analyst hopes.
The price is about 54% above our fair value near $5.7. Analysts expect 32% revenue growth. We see risk if growth or profits weaken.
Breaks if: Fail to execute or reverse exchange agreements in 2026-Q2
Complete exchange transactions to reduce debt by approximately $23 million and manage capital structure.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
XERS represents a speculative growth investment with a focus on improving profitability and revenue. The current thesis state is intact, despite recent mixed signals and a muted price reaction.
The market appears to be pricing in a durable premium compared to peers, reflecting expectations for continued growth. However, the valuation is considered unjustified given the company's loss-making status and recent earnings miss.
Fundamentals show potential for improvement, as management is focused on increasing revenue guidance and maintaining positive net income. Recent financial performance has been strong, but risks remain due to the high-miss-rate nature of the industry.
The thesis hinges on management's ability to deliver on revenue guidance and navigate potential sector challenges. Key factors include the performance of sector bellwethers and overall economic conditions that could impact investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company increased its revenue guidance for 2026, which supports growth. However, it also reported a miss on earnings, which weakens the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q2. Management completed privately negotiated exchange agreements that eliminated approximately $23 million of debt through cash and stock issuance. This action reflects active capital allocation management to strengthen the balance sheet. No prior quarters mention this, so progress is recent and specific.
“Completed exchange agreements eliminating approximately $23 million of debt through cash and stock issuance.”
Breaks if: Net income falls below zero over next 4 quarters
Breaks if: Revenue falls below $380 million in FY26
Drive growth in net product revenue, especially Recorlev, and tighten full-year 2026 revenue guidance to $385-$390 million.
Stated as a priority in 2 of last 2 quarters. Management raised and then tightened full-year 2026 revenue guidance from $380–$390 million in Q1 to $385–$390 million in Q2. Total revenue grew from $83.1 million in 2026-Q1 to $92.1 million in 2026-Q2, driven by strong product revenue growth, especially Recorlev. The trajectory is delivering consistent growth and management confidence.
“We are tightening our full-year guidance to $385–$390 million, reflecting confidence in the team, portfolio, and trajectory.”
“We remain confident in our ability to deliver on full-year financial targets and raised bottom end of 2026 revenue guidance to $380–$390 million.”
In the next 1-3 years, XERS will need to demonstrate consistent execution to justify its current valuation amidst elevated risks. Not investment advice.